Ironwood Pharmaceuticals Inc
Затворен
СекторЗдравеопазване
4.3 5.39
Преглед
Промяна на цената на акция
24 ч
Минимум
4.25
Максимум
4.33
Приходи | 11M 51M |
|---|---|
Продажби | 6.5M 113M |
P/E Средно за сектора | 5.468 57.002 |
EPS | 0.31 |
Марж на печалбата | 45.374 |
Служители | 100 |
EBITDA | 6.2M 81M |
Следващи печалби | 9.11.2026 г. |
|---|
Пазарна капитализация | -14M 714M |
|---|---|
Предишно отваряне | -1.09 |
Предишно затваряне | 4.3 |
Настроения в новините
By Acuity
50%
50%
142 / 340 Класиране в Healthcare
Ironwood Pharmaceuticals Inc Графика
Миналото представяне не гарантира бъдещи резултати.
Свързани новини
Сравнение с други в отрасъла
Ценова промяна
Ironwood Pharmaceuticals Inc Прогноза
Настроение
By Acuity
142 / 340 Класиране в Здравеопазване
Настроения в новините
Neutral
Волатилност
Под средното
Обем новини (RCV)
Под средното
Финанси
Продажбени и админисративни разходи
Оперативни разходи
Печалба преди облагане с данъци
Продажби
Разходи за продажби
Брутна печалба от продажби
Разходи за лихви по дълг
EBITDA
Оперативна печалба
$
Относно Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.